Encapsulating peritoneal sclerosis (EPS) is a serious complication of long-term continuous peritoneal dialysis therapy. The progression of EPS has been classified into four stages by Kawanishi and colleagues: pre-EPS, and the inflammatory, encapsulating, and ileus stages. The key issue is how to diagnose EPS early enough to allow for curative treatment. In this article, we review the mechanisms of peritoneal fibrosis, especially from the perspective of collagen synthesis, and the potential role of that fibrosis in the pathogenesis of EPS.
KawaguchiY., KawanishiH., MujaisS., TopleyN., OreopoulosD.G.Encapsulating peritoneal sclerosis: Definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis.Perit Dial Int2000; 20(Suppl 4): S43–55.
2.
NomotoY., KawaguchiY., SakaiS., HiranoH., KuboH., OhiraS.Sclerosing encapsulating peritonitis (SEP) in patients on continuous ambulatory peritoneal dialysis—definition, diagnosis, and treatment recommendations, 1997 update (Japanese).J Jpn Soc Dial Ther1998; 31: 303–11.
3.
KawanishiH., HaradaY., NoriyukiT., KawaiT., TakahashiS., MoriishiM.Treatment options for encapsulating peritoneal sclerosis based on progressive stage.Adv Perit Dial2001; 17: 200–4.
4.
CombetS., FerrierM.L., Van LandschootM., StoenoiuM., MoulinP., MiyataT.Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum.J Am Soc Nephrol2001; 12: 2146–57.
5.
HondaK., NittaK., HoritaS., YumuraW., NiheiH., NagaiR.Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration.Nephrol Dial Transplant1999; 14: 1541–9.
6.
WilliamsJ.D., CraigK.J., TopleyN., Von RuhlandC., FallonM., NewmanG.R., for the Peritoneal Biopsy Study Group. Morphological changes in the peritoneal membrane of patients with renal disease.J Am Soc Nephrol2002; 13: 470–9.
7.
MargettsP.J., KolbM., YuL., HoffC.M., GauldieJ.A chronic inflammatory infusion model of peritoneal dialysis in rats.Perit Dial Int2001; 21(Suppl 3): S368–72.
8.
NakamotoH., ImaiH., IshidaY., YamanouchiY., InoueT., OkadaH.New animal models for encapsulating peritoneal sclerosis—role of acidic solution.Perit Dial Int2001; 21(Suppl 3): S349–53.
9.
SugaH., TeraokaS., OtaK., KomemushiS., FurutaniS., YamauchiS.Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats.Exp Toxicol Pathol1995; 47: 287–91.
10.
IshiiY., SawadaT., ShimizuA., TojimbaraT., NakajimaI., FuchinoueS.An experimental sclerosing encapsulating peritonitis model in mice.Nephrol Dial Transplant2001; 16: 1262–6.
11.
Yanez–MoM., Lara–PezziE., SelgasR., Ramirez–HuescaM., Dominguez–JimenezC., Jimenez–HeffernanJ.A.Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells.N Engl J Med2003; 348: 403–13.
12.
NakaiA., SatohM., HirayoshiK., NagataK.Involvement of the stress protein HSP47 in procollagen processing in the endoplasmic reticulum.J Cell Biol1992; 117: 903–14.
13.
MasudaH., FukumotoM., HirayoshiK., NagataK.Coexpression of the collagen-binding stress protein HSP47 gene and the α1(I) and α1(III) collagen genes in carbon tetrachloride-induced rat liver fibrosis.J Clin Invest1994; 94: 2481–8.
14.
IwashitaT., KadotaJ., NaitoS., KaidaH., IshimatsuY., MiyazakiM.Involvement of collagen-binding heat shock protein 47 and procollagen type I synthesis in idiopathic pulmonary fibrosis: Contribution of type II pneumocytes to fibrosis.Hum Pathol2000; 31: 1498–505.
15.
RazzaqueM.S., AhsanN., TaguchiT.Heat shock protein 47 in renal scarring.Nephron2000; 86: 339–41.
16.
ShioshitaK., MiyazakiM., OzonoY., AbeK., TauraK., HaradaT.Expression of heat shock proteins 47 and 70 in the peritoneum of patients on continuous ambulatory peritoneal dialysis.Kidney Int2000; 57: 619–31.
17.
MishimaY., MiyazakiM., AbeK., OzonoY., ShioshitaK., XiaZ.Enhanced expression of heat shock protein 47 in rat model of peritoneal fibrosis.Perit Dial Int2003; 23: 14–22.
18.
NishinoT., MiyazakiM., AbeK., FurusuA., MishimaY., HaradaT.Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats.Kidney Int2003; 64: 887–96.
YoshioY., MiyazakiM., AbeK., NishinoT., FurusuA., MizutaY.TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model.Kidney Int2004; 66: 1677–85.
21.
MargettsP.J., GyorffyS., KolbM., YuL., HoffC.M., HolmesC.J.Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats.J Am Soc Nephrol2002; 13: 721–8.
22.
LuftF.C.Proinflammatory effects of angiotensin II and endothelin: Targets for progression of cardiovascular and renal diseases.Curr Opin Nephrol Hypertens2002; 11: 59–66.
AbeK., MiyazakiM., YoshioY., NishinoT., FurusuA., HaradaT.Angiotensin II blockade ameliorates peritoneal fibrosis and angiogenesis in mouse experimental model of peritoneal fibrosis caused by chlorhexidine gluconate (Abstract).J Am Soc Nephrol2002; 13: 309A.
25.
SawadaT., IshiiY., TojimbaraT., NakajimaI., FuchinoueS., TeraokaS.The ACE inhibitor quinapril ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice.Pharmacol Res2002; 46: 505–10.
26.
MargettsP.J., KolbM., GaltT., HoffC.M., ShockleyT.R., GauldieJ.Gene transfer of transforming growth factor-β1 to the rat peritoneum: Effects on membrane function.J Am Soc Nephrol2001; 12: 2029–39.
27.
ImaiH., NakamotoH., FukushimaR., IshidaY., YamanouchiY., SuzukiH.Role of adhesion molecules in the progression of peritoneal sclerosis.Adv Perit Dial2003; 19: 180–5.
28.
MasunagaY., MutoS., AsakuraS., AkimotoT., HommaS., KusanoE.Ascites from patients with encapsulating peritoneal sclerosis augments NIH/3T3 fibroblast proliferation.Ther Apher Dial2003; 7: 486–93.
29.
MargettsP.J., KolbM., YuL., HoffC.M., HolmesC.J., AnthonyD.C.Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum.Am J Pathol2002; 160: 2285–94.
30.
KatoS., YuzawaY., TsuboiN., MaruyamaS., MoritaY., MatsuguchiT.Endotoxin-induced chemokine expression in murine peritoneal mesothelial cells: The role of toll-like receptor 4.J Am Soc Nephrol2004; 15: 1289–99.
31.
BiragynA., RuffiniP.A., LeiferC.A., KlyushnenkovaE., ShakhovA., ChertovO.Toll-like receptor 4–dependent activation of dendritic cells by β-defensin 2.Science2002; 298: 1025–9.
32.
ZarrinkalamK.H., LeavesleyD.I., StanleyJ.M., AtkinsG.J., FaullR.J.Expression of defensin antimicrobial peptides in the peritoneal cavity of patients on peritoneal dialysis.Perit Dial Int2001; 21: 501–8.
33.
HurstS.M., WilkinsonT.S., McLoughlinR.M., JonesS., HoriuchiS., YamamotoN.IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation.Immunity2001; 14: 705–14.
34.
Zuany–AmorimC., HastewellJ., WalkerC.Toll-like receptors as potential therapeutic targets for multiple diseases.Nat Rev Drug Discov2002; 1: 797–807.
35.
SulaimanH., DawsonL., LaurentG.J., BellinganG.J., HerrickS.E.Role of plasminogen activators in peritoneal adhesion formation.Biochem Soc Trans2002; 30: 126–31.
36.
OpatrnyK.Jr., OpatrnaS., VitL., OpatrnyK.Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis.Am J Nephrol1998; 18: 186–92.
37.
RougierJ.P., GuiaS., HagegeJ., NguyenG., RoncoP.M.PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: Transcriptional regulation by TGF-β1.Kidney Int1998; 54: 87–98.
38.
SitterT., Mandl–WeberS., WornleM., HaslingerB., GoeddeM., KooistraT.d-Glucose increases the synthesis of tissue-type plasminogen activator (t-PA) in human peritoneal mesothelial cells.Thromb Haemost1999; 82: 1171–6.
39.
WattersW.B., BuckR.C.Scanning electron microscopy of mesothelial regeneration in the rat.Lab Invest1972; 26: 604–9.
40.
RyanG.B., GrobetyJ., MajnoG.Mesothelial injury and recovery.Am J Pathol1973; 71: 93–112.
41.
NagyJ.A., ShockleyT.R., MasseE.M., HarveyV.S., HoffC.M., JackmanR.W.Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface.Gene Ther1995; 2: 402–10.
42.
NagyJ.A., ShockleyT.R., MasseE.M., HarveyV.S., JackmanR.W.Mesothelial cell-mediated gene therapy: Feasibility of an ex vivo strategy.Gene Ther1995; 2: 393–401.
43.
HoffC.M., CusickJ.L., MasseE.M., JackmanR.W., NagyJ.A., ShockleyT.R.Modulation of transgene expression in mesothelial cells by activation of an inducible promoter.Nephrol Dial Transplant1998; 13: 1420–9.
44.
HekkingL.H., HarveyV.S., HavenithC.E., van den BornJ., BeelenR.H., JackmanR.W.Mesothelial cell transplantation in models of acute inflammation and chronic peritoneal dialysis.Perit Dial Int2003; 23: 323–30.
45.
YoshioY., MiyazakiM., AbeK., MiyazakiM., JinnouchiS., FunakoshiS.Roles of bone marrow derived cells in experimental mouse peritoneal fibrosis (Abstract).J Am Soc Nephrol2003; 14: 477A.
